Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Keytruda = $265,000 (17 doses per year)

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston Apr 14, 2023 9:47am

167 Views

Post# 35394917

RE:RE:RE:RE:Keytruda = $265,000 (17 doses per year)

Rump ... Roswell Park is not a pharma. Simply an hospital like Princess Margaret Cancer Center, McGill University Health Center, etc ...

We will get a suitor as our costs will be lower, the burden on the healthcare will be lower, the toxicity on patients will be lower. So there will be pressure on big pharmas to lower costs, etc ... by public health care systems, private clinics, etc ... So one big pharma will make a move faster than it's competitors.

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta